Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1861 to 1870 of 2575 total matches.

Quinupristin/Dalfopristin

   
The Medical Letter on Drugs and Therapeutics • Nov 19, 1999  (Issue 1066)
and -resistant Streptococcus pneumoniae (RG Finch, Drugs, 51 suppl 1:31, 1996). It also is active in vitro ...
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection....
Med Lett Drugs Ther. 1999 Nov 19;41(1066):109-10 |  Show IntroductionHide Introduction

Fluoxetine Sarafem For Premenstrual Dysphoric Disorder

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001  (Issue 1096)
Halbreich et al and EW Freeman et al, Int J Neuropsychopharmacol July 2000; 3 suppl 1:S248 and S241 ...
Fluoxetine, a selective serotonin reuptake inhibitor (SSRI) previously sold only as Prozac, is now also marketed as Sarafem for treatment of premenstrual dysphoric disorder (PMDD). Generic fluoxetine is expected to be available sometime this year.
Med Lett Drugs Ther. 2001 Jan 22;43(1096):5-6 |  Show IntroductionHide Introduction

A New Snake Antivenom

   
The Medical Letter on Drugs and Therapeutics • Jun 25, 2001  (Issue 1107)
is available from Savage Laboratories (1-800-2310206). The cost of 12 vials would be $9,300. Although ...
CroFab, an antigen-binding-fragment (Fab) antivenom of ovine origin, has been approved by the FDA for treatment of North American rattlesnake envenomation.
Med Lett Drugs Ther. 2001 Jun 25;43(1107):55-6 |  Show IntroductionHide Introduction

Zoledronate (Zometa)

   
The Medical Letter on Drugs and Therapeutics • Dec 10, 2001  (Issue 1120)
%) (JP Brown et al, J Bone Miner Res 2001; 16 suppl 1:S218, abstract F353). ADVERSE EFFECTS — Adverse ...
Zoledronic acid (Zometa), a new bisphosphonate, has been approved by the FDA for intravenous (IV) treatment of hypercalcemia of malignancy.
Med Lett Drugs Ther. 2001 Dec 10;43(1120):110-1 |  Show IntroductionHide Introduction

Pegfilgrastim (Neulasta) For Prevention of Febrile Neutropenia

   
The Medical Letter on Drugs and Therapeutics • May 13, 2002  (Issue 1130)
al, Blood 2001; 98 (11 part 1):799a, abstract 3322). No data are available on use of pegfilgrastim ...
Recombinant human granulocyte colony stimulating factor (G-CSF, filgrastim) conjugated to polyethylene glycol (pegfilgrastim, Neulasta - Amgen) has been approved by the FDA for use in neutropenic patients with non-myeloid malignancies who are at high risk for infection. Filgrastim (Neupogen - Amgen) has been available in the US since 1991.
Med Lett Drugs Ther. 2002 May 13;44(1130):44-5 |  Show IntroductionHide Introduction

Anastrozole (Arimidex) vs. Tamoxifen for Treatment of Early Breast Cancer

   
The Medical Letter on Drugs and Therapeutics • Mar 17, 2003  (Issue 1152)
in postmenopausal women. It suppresses serum estrogen to 1%-10% of pre-treatment levels. PHARMACOKINETICS ...
Anastrozole (Arimidex - AstraZeneca, Medical Letter 1996; 38:61), an aromatase inhibitor, has received accelerated approval from the FDA for adjuvant treatment of postmenopausal women with early hormone-receptor-positive breast cancer. The drug was approved for treatment of postmenopausal women with metastatic breast cancer in 1996.
Med Lett Drugs Ther. 2003 Mar 17;45(1152):22-3 |  Show IntroductionHide Introduction

Zingo for Local Analgesia in Children

   
The Medical Letter on Drugs and Therapeutics • Aug 25, 2008  (Issue 1293)
Publication 1. WT Zempsky et al. A novel needle-free powder lidocaine delivery system for rapid local ...
The FDA has approved the marketing of a new device for delivering lidocaine to the skin of children undergoing a venipuncture or intravenous (IV) line placement. Zingo (Anesiva) is a powder intradermal injection system.
Med Lett Drugs Ther. 2008 Aug 25;50(1293):68 |  Show IntroductionHide Introduction

In Brief: New Propellants for Albuterol Metered-Dose Inhalers

   
The Medical Letter on Drugs and Therapeutics • Nov 03, 2008  (Issue 1298)
Publication New Propellants for Albuterol Metered-Dose Inhalers IN BRIEF Drug Dosage 1 Cost 2 ...
Inhaled drugs for asthma are available in the US mainly in pressurized metered-dose inhalers (MDIs), which require a propellant, and dry powder inhalers, which do not. The chlorofluorocarbon (CFC) propellants in MDIs are being replaced by hydrofluoroalkane (HFA) propellants for environmental reasons: CFCs contribute to the depletion of the ozone layer. December 31, 2008 will be the last day that albuterol MDIs using CFC propellants can be sold in the US. The FDA is expected to announce a termination date for other CFC-containing products in the near future.Three HFA albuterol inhalers and one...
Med Lett Drugs Ther. 2008 Nov 3;50(1298):85 |  Show IntroductionHide Introduction

Vaccines and Pregnancy

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2011  (Issue 1378)
Guidelines from The Medical Letter.1 BEFORE PREGNANCY — Inactivated vaccines can be given at any time ...
Live-attenuated vaccines are generally contraindicated during pregnancy; inactivated vaccines can be given if indicated. A more detailed review of routine immunizations for adults will be available in the December issue of Treatment Guidelines from The Medical Letter.
Med Lett Drugs Ther. 2011 Nov 28;53(1378):94-6 |  Show IntroductionHide Introduction

Epidural Corticosteroid Injections for Lumbar and Cervical Radiculopathy

   
The Medical Letter on Drugs and Therapeutics • Jan 23, 2012  (Issue 1382)
and Cervical Radiculopathy For patients with radicular pain unresponsive to conservative treatment after 1-2 ...
For patients with radicular pain unresponsive to conservative treatment after 1-2 months and no progressive neurologic deficit, epidural corticosteroid injections are often tried before surgical intervention.
Med Lett Drugs Ther. 2012 Jan 23;54(1382):5-6 |  Show IntroductionHide Introduction